JP2003513039A5 - - Google Patents

Download PDF

Info

Publication number
JP2003513039A5
JP2003513039A5 JP2001534373A JP2001534373A JP2003513039A5 JP 2003513039 A5 JP2003513039 A5 JP 2003513039A5 JP 2001534373 A JP2001534373 A JP 2001534373A JP 2001534373 A JP2001534373 A JP 2001534373A JP 2003513039 A5 JP2003513039 A5 JP 2003513039A5
Authority
JP
Japan
Prior art keywords
antioxidant
composition
carnitine
administered
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534373A
Other languages
English (en)
Other versions
JP2003513039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030571 external-priority patent/WO2001032168A1/en
Publication of JP2003513039A publication Critical patent/JP2003513039A/ja
Publication of JP2003513039A5 publication Critical patent/JP2003513039A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 抗酸化剤、およびカルニチン、ならびに必要に応じて補酵素Ｑおよび／またはクレアチンを含有する、老化に伴う記憶障害を治療するための組成物。
【請求項２】 カルニチンがＡＬＣであり、かつ抗酸化剤が０．５ｇから３ｇの量で投与されることを特徴とする請求項１記載の組成物。
【請求項３】 抗酸化剤がＲ−α−リポ酸であることを特徴とする請求項１記載の組成物。
【請求項４】 前記抗酸化剤が０．２５ｇから１．５ｇの量で投与されることを特徴とする請求項１記載の組成物。
JP2001534373A 1999-11-03 2000-11-02 良性の健忘症を治療する方法 Pending JP2003513039A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16335299P 1999-11-03 1999-11-03
US60/163,352 1999-11-03
US22316700P 2000-08-07 2000-08-07
US60/223,167 2000-08-07
PCT/US2000/030571 WO2001032168A1 (en) 1999-11-03 2000-11-02 Method of treating benign forgetfulness

Publications (2)

Publication Number Publication Date
JP2003513039A JP2003513039A (ja) 2003-04-08
JP2003513039A5 true JP2003513039A5 (ja) 2006-01-05

Family

ID=26859574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534373A Pending JP2003513039A (ja) 1999-11-03 2000-11-02 良性の健忘症を治療する方法

Country Status (5)

Country Link
US (1) US6335361B1 (ja)
EP (1) EP1248609A4 (ja)
JP (1) JP2003513039A (ja)
CA (1) CA2389623A1 (ja)
WO (1) WO2001032168A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8592479B2 (en) * 2000-10-31 2013-11-26 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals
US20090156658A1 (en) * 2000-10-31 2009-06-18 Hill's Pet Nutrition, Inc. Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals
AU2002232616A1 (en) * 2000-10-31 2002-06-11 Colgate-Palmolive Company Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin C or vitamin E for preventing or inhibiting loss of cognitive function
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
WO2002071874A2 (en) * 2001-03-09 2002-09-19 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
DE10125901A1 (de) * 2001-05-28 2002-12-05 Basf Ag Kombination von Liponsäuren, Carnitinen und Kreatinen in Lebens- und Arzneimitteln
US6923960B2 (en) 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
EP1523326A4 (en) 2002-05-06 2009-09-09 Univ Jefferson INSULIN-RELATED PEPTIDES HAVING EFFECTS ON BRAIN HEALTH
EP1567180A4 (en) * 2002-06-04 2010-03-10 Avicena Group Inc METHODS OF TREATING COGNITIVE DYSFUNCTIONS BY MODULATING BRAIN ENERGY METABOLISM
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US20060165671A1 (en) * 2002-11-07 2006-07-27 Daniel Raederstorff Novel nutraceutical compositions comprising epigallocatechin gallate
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20050102171A1 (en) * 2003-10-29 2005-05-12 Ashley Thomas R. Elderly assessment protocol
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
ES2436181T3 (es) * 2004-12-29 2013-12-27 Hill's Pet Nutrition Inc. Métodos para inhibir un declive en el aprendizaje y/o la memoria en animales
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
EP2194140A2 (en) * 2005-03-02 2010-06-09 Metanomics GmbH Process for the production of fine chemicals
WO2007009111A1 (en) 2005-07-14 2007-01-18 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
WO2007119578A1 (ja) 2006-03-29 2007-10-25 Kaneka Corporation 神経系細胞機能改善剤
EP2023914A4 (en) * 2006-05-11 2009-11-11 Avicena Group Inc METHODS OF TREATING NEUROLOGICAL DISORDER WITH CREATIN MONOHYDRATE
JP5119509B2 (ja) * 2006-05-18 2013-01-16 ビーエイチエヌ株式会社 活動意欲向上剤
US9308232B2 (en) 2006-06-05 2016-04-12 Keyview Labs, Inc. Compositions and methods for enhancing brain function
WO2007145993A2 (en) * 2006-06-05 2007-12-21 Brite Age Modified compositions and methods for enhancing brain function
US8071610B2 (en) * 2006-06-05 2011-12-06 Josh Reynolds Compositions and methods for enhancing brain function
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US10105406B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A, Ginkgo biloba, and vitamin B complex
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
US10105405B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A and ginkgo biloba
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
JP2008214338A (ja) * 2007-02-08 2008-09-18 Shiseido Co Ltd 高次脳機能低下改善剤および遅延記憶低下改善剤
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
JP5157007B2 (ja) * 2007-05-11 2013-03-06 ビーエイチエヌ株式会社 骨強化剤
DE102007030495A1 (de) 2007-06-30 2009-01-15 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
ES2640777T3 (es) 2009-12-30 2017-11-06 Baylor Research Institute Terapia anaplerótica para la enfermedad de Alzheimer
US9468229B2 (en) 2012-12-13 2016-10-18 National Institute Of Health And Medical Research Triheptanoin for the treatment of glucose transport 1 deficiency
EP3689343A1 (en) 2013-11-14 2020-08-05 The University of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof using anaplerotic agents
JP2015193582A (ja) * 2014-03-28 2015-11-05 国立大学法人 東京大学 イミダゾールジペプチドを含む剤
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
IT1156840B (it) 1978-06-27 1987-02-04 Sigma Tau Ind Farmaceuti Acil derivati della carnitina
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1145362B (it) 1980-03-06 1986-11-05 Sigma Tau Ind Farmaceuti Classe di acil-derivati della carnitina procedimento per la loro preparazione e loro uso terapeutico
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
IT1230142B (it) 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
US5240961A (en) 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
US5916912A (en) 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil

Similar Documents

Publication Publication Date Title
JP2003513039A5 (ja)
DE69927125D1 (de) Zusammensetzung gegen Erhöhung oder zur Herabsetzung des Blutzuckerspiegels
FR2807322B1 (fr) Composition, notamment cosmetique, comprenant de l'acide ascorbique en association avec un derive d'acide ascorbique
CA2201264A1 (en) Immediate release ph-independent solid dosage form of cisapride
WO2001062290A3 (en) Methods and compositions for improving sleep
AU3221599A (en) Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IL145344A0 (en) Food complement and method for cosmetic treatment based on a grape extract rich in polyphenols
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
DE60131663D1 (de) Acylacetonitrile, deren herstellung und diese enthaltende miticide
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2002009679A3 (en) Use of 13-cis retinoic acid for the treatment of emphysema
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
PL354413A1 (en) Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts ofginkgo biloba
JP2002051693A5 (ja)
AU2001242130A1 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CA2417837A1 (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
CA2438622A1 (en) Compositions containing creatine and creatinine
EP1090635A3 (en) Use of ferulic acid for treating hypertension
EP1709960A3 (en) Use of alkanoic acid-containing compositions for straightening hair
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2003094905A8 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
WO2004074216A3 (en) Carnitine salt, preliposome which contains it and dermo-cosmetic formula for topical use based upon said carnitine salt
FR2909556B1 (fr) Creme photoprotectrice a base d'acide gras
JP2003501387A5 (ja)